

Test Charts

UPDATED APRIL 2026



1 After a PSA Test

TEST	USE	SPECIMEN TYPE	INDICATIONS	SCIENCE	RESULTS	COST	COVERED BY MEDICARE?	COVERED BY PRIVATE INSURANCE PLANS?	FINANCIAL ASSISTANCE #
4Kscore	<ul style="list-style-type: none"> Whom to biopsy Identify Significant PCa 	Blood	Men with abnormal PSA or DRE	Measures 4 kallikreins (proteins) in the blood (Total PSA, FreePSA, Intact PSA and hK2) and combines with clinical information	Provides the percent probability, ranging from 1-95%, to determine if there is low, moderate, or high risk of significant cancer on biopsy	\$600–\$1,100*	Yes	Yes	(855) 452-4554
Prostate Health Index (phi)	<ul style="list-style-type: none"> Whom to biopsy Identify Significant PCa 	Blood	Men with PSA between 2-10ng/ml (4-10ng/ml USFDA)	Measures concentrations of PSA, free PSA and pro2PSA in a formula that produces the phi score	Identifies four categories of risk that prostate cancer may be found on biopsy	\$100–\$200*	Yes	Yes	(305) 380-3800
Exo MDx	<ul style="list-style-type: none"> Whom to biopsy Identify Significant prostate cancer 	Urine (no DRE)	Men 50+ years of age with a PSA 2-10 ng/ml	Exo MDx analyzes exosomal RNA for three biomarkers known to be expressed in men with high-grade prostate cancer with at-home collection available	An increasing Exo MDx score correlates with greater risk of High Grade Prostate Cancer on biopsy	Financial assistance available for patients	Yes	Yes	(866)-259-5644
Ambry Genetics ProstateNext	<ul style="list-style-type: none"> Identify patients with a genetic disposition to prostate and other cancers to: Inform screening & medical management options Identify at-risk family members 	Blood or Saliva	Men with any of the following: <ul style="list-style-type: none"> Multiple prostate or related cancers in personal and/or family history Early onset or metastatic prostate cancers 	14-gene test including full gene sequencing and deletion/duplication analysis.	Positive, negative, or variant of unknown significance (VUS) are possible results. Positive results are accompanied by clinical management resources for clinicians and patients.	Under Ambry's Patient Assistance Program: <ul style="list-style-type: none"> 4 out of 5 patients pay \$0 Average cost for patients who do pay is less than \$100 	Yes	Yes	(949) 900-5795

2 After a Biopsy

TEST	USE	SPECIMEN TYPE	INDICATIONS	SCIENCE	RESULTS	COST	COVERED BY MEDICARE?	COVERED BY PRIVATE INSURANCE PLANS?	FINANCIAL ASSISTANCE #
Confirm MDx	<ul style="list-style-type: none"> History of negative prostate biopsy (no cancer) Whom to rebiopsy 	Negative biopsy tissue	Previous negative biopsy	Three-genes to detect an epigenetic (cancer) field effect	<ul style="list-style-type: none"> Negative ConfirmMDx result: <i>Avoid repeat biopsy and monitor with routine screening</i> Positive ConfirmMDx result: <i>Consider further evaluation and rebiopsy</i> 	\$3,300* Financial assistance available for patients	Yes	Yes	(866)-259-5644
Genomic Prostate Score (GPS MDx)	<ul style="list-style-type: none"> GS 6 Biopsy Whom to consider for Active Surveillance 	Positive biopsy tissue	Men diagnosed with localized prostate cancer	Assay looks at 17 genes within 4 pathways (androgen signaling, stromal response, cellular organization, proliferation) to assess tumor aggressiveness	<ul style="list-style-type: none"> Genomic Prostate Score (GPS MDx) from 0 to 100 GPS MDx predicts the likelihood of: <ul style="list-style-type: none"> Adverse pathology (\geqpT3a and/or GG3 GS 4+3) High-grade disease (GG3, GS 4+3) Non-organ confined disease (\geqpT3a) 10-year metastasis 10-year prostate cancer specific mortality 	\$4,180* Financial assistance available for patients	Yes	Yes	(866) 259-5644
Decipher Prostate Biopsy	<ul style="list-style-type: none"> Positive Biopsy Whom to treat and intensify treatment Whom to consider for active surveillance 	Biopsy tissue	Men with localized disease on biopsy	<ul style="list-style-type: none"> Whole Transcriptome Microarray A panel of molecular biomarkers specific to prostate cancer progression and metastasis represented by multiple biological pathways 	Decipher predicts the likelihood of: <ul style="list-style-type: none"> High grade disease 5-year metastasis 10-year prostate cancer specific mortality 	Financial assistance available for patients	Yes	Yes	(888) 792-1601
Prolaris	<ul style="list-style-type: none"> Positive Biopsy Whom to treat Whom to consider for active surveillance 	Tissue	Measures patient's eligibility of definitive therapy or active surveillance	Analyzes positive cancer tissue from a previous prostate biopsy. The genetic test evaluates a patient's National Comprehensive Cancer Network risk category as compared to the results of 46-gene expressions	Prolaris provides an analysis of individual tumor aggressiveness as well as a clinically validated prostate cancer-specific mortality risks	\$3,400*	Yes	Yes	(844) 697-4239

3 Prostate Cancer Treatment

TEST	USE	SPECIMEN TYPE	INDICATIONS	SCIENCE	RESULTS	COST	COVERED BY MEDICARE?	COVERED BY PRIVATE INSURANCE PLANS?	FINANCIAL ASSISTANCE #
Decipher Prostate RP	<ul style="list-style-type: none"> Post Radical Prostatectomy (RP) Who and when to treat 	RP Tissue	Men with adverse pathology after prostatectomy: <ul style="list-style-type: none"> Positive Surgical Margins (SM+) Extraprostatic extension (EPE) Seminal Vesicle Invasion Bladder Neck Invasion Rising PSA or BCR 	<ul style="list-style-type: none"> Whole Transcriptome Microarray A panel of molecular biomarkers specific to prostate cancer progression and metastasis represented by multiple biological pathways 	Decipher provides the likelihood of: <ul style="list-style-type: none"> 5-year metastasis 10-year prostate cancer specific mortality 	Financial assistance available for patients	Yes	Yes	(888) 792-1601

4 Recurrence

TEST	USE	SPECIMEN TYPE	INDICATIONS	SCIENCE	RESULTS	COST	COVERED BY MEDICARE?	COVERED BY PRIVATE INSURANCE PLANS?	FINANCIAL ASSISTANCE #
Myriad MyRisk	<ul style="list-style-type: none"> For patients with a family history or personal past of hereditary cancer, the test provides clear results that can be foundational to a personalized care plan Whom to treat for recurrent prostate cancer 	Saliva	Men with any of the following: <ul style="list-style-type: none"> Multiple prostate or related cancers in personal and/or family history Early onset or metastatic prostate cancers 	Evaluates 48 genes to help identify a patient's risk of 11 different types of hereditary cancer	<ul style="list-style-type: none"> Positive Result: A genetic mutation was found in one or more genes tested, putting the patient at increased risk for cancer Elevated Result: No genetic mutation was found, but the patient is at elevated risk of cancer based on family history, personal risk factors or additional genetic markers Negative Result: No genetic mutation was found in the genes tested. Risk for cancer depends on personal or family history Variant of Uncertain Significance: A change in a gene was identified, but it is not yet known if this change is associated with increased cancer risk 	\$0—\$42	Yes	Yes	(866) 259-5644
ProstateNext	Identify patients with a genetic predisposition to prostate and other cancers to: <ul style="list-style-type: none"> Inform screening and medical management options Identify at-risk family members 	Blood or Saliva	Men with any of the following: <ul style="list-style-type: none"> Multiple prostate or related cancers in personal and/or family history Early onset or metastatic prostate cancers 	14-gene test including full gene sequencing and deletion/duplication analysis	Positive, negative, or variant of unknown significance (VUS) are possible results. Positive results are accompanied by clinical management resources for clinicians and patients	Under Ambry's Patient Assistance Program: <ul style="list-style-type: none"> 4 out of 5 patients pay \$0 Average cost for patients who do pay is less than \$100 	Yes	Yes	(949) 900-5795

5 Advanced Prostate Cancer

TEST	USE	SPECIMEN TYPE	INDICATIONS	SCIENCE	RESULTS	COST	COVERED BY MEDICARE?	COVERED BY PRIVATE INSURANCE PLANS?	FINANCIAL ASSISTANCE #
AR-V7 by Epic Sciences	<ul style="list-style-type: none"> Response to androgen receptor (AR) targeted therapies or if chemotherapy should be recommended instead Whom to treat for advanced prostate cancer 	Blood	Men who have been diagnosed with late-stage prostate cancer	Patient will have blood drawn and sent by their physician to epic sciences laboratory for processing of localized AR-V7+ CTCs. Here, they can characterize all of the circulating tumor cells and predict their response of resistance to a class of drugs.	Results are reported back to the physician as either AR-V7+(positive) or AR-V7-(negative)	Customer Success contacts patient if expected out of pocket payment exceeds >\$100 after insurance. Patient can also complete Epic's Financial Assistance Program (FAP) application at the time of test order (see link below) or Customer Success can assist with an application.	Yes	Yes	(800) 941-0522